Qiagen N.V. QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

 

QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer

Venlo, the Netherlands, August 24, 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare.

Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corporation in August 2026. He previously served as Senior Vice President of the Waters Division at Waters Corporation and as President of Beckman Coulter Life Sciences, a Danaher operating company, and held senior leadership positions at Pall Corporation.

Throughout his career, he has led global businesses spanning analytical instruments, laboratory technologies, software, consumables, services and bioprocessing applications. His experience includes commercial execution, portfolio management, operations and organizational development in markets closely aligned with QIAGEN’s portfolio and customer workflows.

He will also be proposed for shareholder approval as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026.

Thierry Bernard will step down as CEO and Managing Director and will support an orderly transition through the end of the year.

QIAGEN has reaffirmed its outlook for the third quarter and full-year 2026. QIAGEN remains focused on delivering solid profitable growth by advancing its growth pillars, improving operating efficiency and allocating capital to the highest-return opportunities.

As previously communicated, the Supervisory Board continues to evaluate opportunities, with independent financial and legal advisors, as part of its strategic review to create value for shareholders and other stakeholders relative to QIAGEN’s standalone business plan and long-term strategic objectives.

QIAGEN N.V. 

Hulsterweg 82 

5912 PL Venlo 

The Netherlands

 

 

Ad hoc

ISIN: NL0015001WM6

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V. 

Corporate Communications

John Gilardi, Tel: +49 2103 29 11711; pr@qiagen.com